During the last three months, 4 analysts shared their evaluations of Tandem Diabetes Care TNDM, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their ...

Tandem Diabetes Care, Inc. TNDM is driving transformative innovation to help reduce the burden and create new possibilities for people living with diabetes. Its strong focus on overseas expansion is ...

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from ...

Analyst consensus for Tandem Diabetes Care stock has shifted, with the average price target being lowered from $22.62 to $20.76 as Wall Street reconsiders the company’s growth outlook. This adjustment ...

Citi raised the firm’s price target on Tandem Diabetes (TNDM) to $15 from $11 and keeps a Neutral rating on the shares. The firm is cautious on ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor ...